
-
Puma Biotechnology NasdaqGS:PBYI Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Location: 10880 Wilshire Boulevard, Los Angeles, CA, 90024, United States | Website: https://www.pumabiotechnology.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
136.8M
Cash
93.17M
Avg Qtr Burn
N/A
Short % of Float
7.68%
Insider Ownership
15.49%
Institutional Own.
64.31%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NERLYNX Details Breast cancer, Sexual desire disorder, Sexual dysfunction | Approved Quarterly sales | |
NERLYNX Details Breast cancer, Cancer, ER+/HER2- breast cancer, Solid tumor/s | Approved Quarterly sales | |
Neratinib Details Cervical cancer, Infectious disease, Catheter related blood stream infections | Phase 2 Data readout | |
Alisertib Details ER+/HER2- breast cancer, Breast cancer, Cancer | Phase 2 Data readout | |
Phase 2 Data readout | ||
Trastuzumab Emtansine (T-DM1) With Neratinib Details Breast cancer | Phase 2 Update | |
Neratinib Details Lung cancer, Non-small cell lung carcinoma | Phase 2 Update | |
Neratinib Details Bile duct disease, Cancer | Phase 2 Update | |
Neratinib (HKI-272) + fulvestrant + trastzuzumab Details Metastatic breast cancer, Breast cancer, Metastatic breast cancer to brain | Phase 2 Update | |
Alisertib (2 combo trials) Details Breast cancer, ER+/HER2- breast cancer | Phase 2 Update | |
Alisertib Details Cancer, Non-small cell lung carcinoma | Phase 1/2 Update | |
Alisertib+pembrolizumab Details Head and neck squamous cell carcinoma, Cancer | Phase 1/2 Update |